Zenocutuzumab
In clinical developmentAlso known as Bizengri, Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.), Immunoglobulin g1, bispecific, anti-(human epidermal growth factor receptors, her2 and her3) (humanized clone mcla-128 .gamma.1-chain), disulfide with humanized clone mcla-128 light chain, dimer.
Recent clinical, regulatory, research and industry developments relating to this drug.
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes5
Journals, researchers & institutions
- The New England journal of medicine1
- Adeyemi S1
- Bekaii-Saab T1
- Calvo E1
- Cleary JM1
- Drilon A1
- Duruisseaux M1
- Ford J1
- Goto K1
- Abramson Cancer Center1
- Chao Family Comprehensive Cancer Center1
- Curie Institute1
- Dana-Farber Cancer Institute1
- Harvard Medical School1
- Lombardi Comprehensive Cancer Center1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials